Abbott’s drug eluting stents, XIENCE PRIME™ Everolimus Eluting Coronary Stent System and the XIENCE V® Everolimus Eluting Coronary Stent System have both received additional new CE Markings (Conformité Européenne), covering the treatment of patients with diabetes.
The
CE marking certifies that a product has met EU consumer safety, health or environmental requirements.
Coronary artery disease is one of the most common cardiovascular complications of diabetes and is the number one cause of death among European adults with diabetes.
The high blood glucose levels associated with diabetes can lead to increased deposits of fatty materials on the insides of the blood vessel walls. These deposits may affect blood flow to the heart, increasing the chance of clogging and hardening of blood vessels.
Patients with diabetes who also have coronary artery disease often have poorer outcomes after stent procedures because their blood vessels tend to build up more plaque than the vessels of non-diabetic patients, and their coronary artery disease advances more quickly.
"This expanded indication further confirms XIENCE PRIME and XIENCE V as important options for physicians who are treating patients with diabetes," said Charles Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "Patients with diabetes tend to be sicker and have more challenging anatomy, such as small vessels or long lesions, which can be difficult to treat.
The deliverability of both devices provides physicians with confidence to easily reach the lesion site."